Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.) on March 21, 2012. The filing reports a corporate governance event regarding the appointment of a senior financial officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and compensation details.
Material Changes
On March 21, 2012, the Board of Directors appointed Lauren Riker as the Company's Principal Accounting Officer, effective immediately. Ms. Riker had previously served as Executive Director, Accounting and Financial Reporting since May 2011. Additionally, her base salary was increased from $206,000.08 to $211,520, effective January 1, 2012.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The employment arrangement is designated as "at will," allowing for termination by either party at any time with or without cause.
Key Facts for Investor Verification
- Appointment: Lauren Riker appointed Principal Accounting Officer on March 21, 2012.
- Compensation: Base salary increased to $211,520 as of January 1, 2012.
- Equity: Ms. Riker received an option to purchase 40,000 shares of Company stock upon her initial employment offer in March 2011.
- Background: Ms. Riker holds an M.B.A. from Columbia Business School and previously held senior accounting roles at Ikaria, Inc. and Bioenvision, Inc.
- Related Parties: No family relationships exist between Ms. Riker and current directors or executive officers.